Zuzanna Augustyn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zuzanna Augustyn has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Piąta
Zakład Neurologii, Collegium Medicum, Uniwersytet Jana Kochanowskiego w Kielcach, Kielce, Polska
1 shared publication - Dominik Malicki
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
1 shared publication - Dominika Lorek
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
1 shared publication - Jakub Janczura
Faculty of Medicine, Jan Kochanowski University, Kielce, Poland
1 shared publication - Klaudia Nowak
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
1 shared publication - Piotr Starnawski
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
1 shared publication
Latest Publications
- 17 March 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (4) , 1-14
Role of hepatotropic viruses in promoting hepatocellular carcinoma—current knowledge and recent advances
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with chronic infections by hepatotropic viruses such as hepatitis B virus (HBV), and hepatitis C virus (HCV), being major risk factors. Chronic infections with these viruses are the leading cause of HCC worldwide, with HBV alone responsible for over 50% of cases. Despite advances in direct-acting antivirals (DAAs) for HCV and nucleos(t)ide analogues (NAs) for HBV, challenges remain in HCC prevention, early detection, and treatment. Recent research highlights the role of viral-induced metabolic alterations, such as the Warburg effect, mitochondrial dysfunction, and lipid dysregulation, in promoting HCC. Moreover, immune checkpoint inhibitors have emerged as effective treatments for advanced HCC, though responses vary between HBV- and HCV-related cancers. Additionally, novel therapeutic approaches and metabolic-targeted therapies offer promising avenues for virus-associated HCC treatment. Advancements in liquid biopsy biomarkers and artificial intelligence-driven diagnostics are improving HCC surveillance and risk stratification, potentially enabling earlier interventions. While HBV vaccination has significantly reduced HCC incidence, disparities in global vaccination coverage persist. Furthermore, antiviral therapies combined with structured surveillance programs have proven effective in reducing HCC incidence and mortality. This review highlights the complex connection between viral, genetic, and environmental factors in HCC development and underscores the importance of integrated prevention strategies to reduce its burden globally.
- 17 March 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (4) , 1-14
Role of hepatotropic viruses in promoting hepatocellular carcinoma—current knowledge and recent advances
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with chronic infections by hepatotropic viruses such as hepatitis B virus (HBV), and hepatitis C virus (HCV), being major risk factors. Chronic infections with these viruses are the leading cause of HCC worldwide, with HBV alone responsible for over 50% of cases. Despite advances in direct-acting antivirals (DAAs) for HCV and nucleos(t)ide analogues (NAs) for HBV, challenges remain in HCC prevention, early detection, and treatment. Recent research highlights the role of viral-induced metabolic alterations, such as the Warburg effect, mitochondrial dysfunction, and lipid dysregulation, in promoting HCC. Moreover, immune checkpoint inhibitors have emerged as effective treatments for advanced HCC, though responses vary between HBV- and HCV-related cancers. Additionally, novel therapeutic approaches and metabolic-targeted therapies offer promising avenues for virus-associated HCC treatment. Advancements in liquid biopsy biomarkers and artificial intelligence-driven diagnostics are improving HCC surveillance and risk stratification, potentially enabling earlier interventions. While HBV vaccination has significantly reduced HCC incidence, disparities in global vaccination coverage persist. Furthermore, antiviral therapies combined with structured surveillance programs have proven effective in reducing HCC incidence and mortality. This review highlights the complex connection between viral, genetic, and environmental factors in HCC development and underscores the importance of integrated prevention strategies to reduce its burden globally.